KLHDC8B Inhibitors
KLHDC8B inhibitors comprise a select group of chemicals that can modulate the function of the KLHDC8B protein, a member of the Kelch domain-containing family. This family of proteins has been implicated in various cellular processes, especially in interactions with the ubiquitin-proteasome system. Inhibitors targeting KLHDC8B can either act directly or indirectly, depending on their mode of action and their primary targets within the cell. For instance, compounds such as MG-132, Bortezomib, and Lactacystin primarily inhibit the proteasomal degradation mechanism. By preventing the proteasome's proteolytic activity, these inhibitors may influence the ubiquitination status of proteins. KLHDC8B plays a role in targeting specific proteins for degradation, these proteasome inhibitors would likely counteract this by averting the degradation of ubiquitinated substrates. This signifies an indirect way of altering KLHDC8B's presumed function.
On the other hand, compounds like MLN4924 (Pevonedistat), NEM, PR-619, and PYR-41 operate on various components of the ubiquitination cascade. MLN4924, for instance, targets the NEDD8-activating enzyme, potentially disrupting the interactions of KLHDC8B with Cullin-based E3 ligases. Similarly, NEM and PR-619 inhibit deubiquitinating enzymes, potentially modulating KLHDC8B's function by influencing the ubiquitin balance within the cell. PYR-41 inhibits the initial step of the ubiquitination cascade by acting on the ubiquitin-activating enzyme E1. By reducing the availability of ubiquitin, the effectiveness of ubiquitin-transferring functions, which KLHDC8B might be involved in, can be altered.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG-132 inhibits the proteasome's proteolytic activity, which could increase the levels of ubiquitinated proteins. If KLHDC8B has a role in targeting specific proteins for degradation, MG-132 would counteract this by preventing the degradation of such ubiquitinated substrates. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor. By inhibiting the 26S proteasome, it prevents the degradation of ubiquitinated proteins. If KLHDC8B targets certain proteins for ubiquitin-mediated degradation, Bortezomib would negate this effect by inhibiting proteasomal degradation. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $165.00 $575.00 | 60 | |
Lactacystin binds irreversibly to the β-subunits of the proteasome, inhibiting its activity. If KLHDC8B facilitates protein degradation, the action of Lactacystin would increase the ubiquitinated proteins' stability. | ||||||
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $280.00 | 1 | |
MLN4924 inhibits the NEDD8-activating enzyme, blocking Cullin neddylation. If KLHDC8B interacts with Cullin-based E3 ligases, MLN4924 would inhibit this interaction, potentially disrupting KLHDC8B's function in ubiquitin transfer. | ||||||
N-Ethylmaleimide | 128-53-0 | sc-202719A sc-202719 sc-202719B sc-202719C sc-202719D | 1 g 5 g 25 g 100 g 250 g | $22.00 $68.00 $210.00 $780.00 $1880.00 | 19 | |
NEM inhibits deubiquitinating enzymes (DUBs), preventing the removal of ubiquitin chains from substrates. If KLHDC8B's function involves deubiquitination indirectly, NEM would amplify the ubiquitination effect by blocking DUBs. | ||||||
PR 619 | 2645-32-1 | sc-476324 sc-476324A sc-476324B | 1 mg 5 mg 25 mg | $75.00 $184.00 $423.00 | 1 | |
PR-619 is a broad-spectrum inhibitor of deubiquitinating enzymes (DUBs). If KLHDC8B operates in concert with DUBs or its function is influenced by the ubiquitination status of its partners, PR-619 could indirectly affect KLHDC8B's function by influencing the ubiquitin balance. | ||||||
Ubiquitin E1 Inhibitor, PYR-41 | 418805-02-4 | sc-358737 | 25 mg | $360.00 | 4 | |
PYR-41 inhibits the ubiquitin-activating enzyme E1. By blocking E1, PYR-41 reduces the ubiquitination of proteins. If KLHDC8B facilitates ubiquitin transfer, the availability of ubiquitin would be decreased, potentially reducing KLHDC8B's effectiveness. | ||||||